Farmas USA

SGYP
Approval esperado dado el profile pero no esperaba hoy! Bien!

David Apelian, Achillion Pharmaceuticals's Chief Medical Officer, just received 185,000 options from the company. The strike price of the options received was $4.11, and these expire on January 17, 2027. Apelian now owns at least 185,000 options on the company

http://www.conferencecalltranscripts.org/4/summary2/?id=3400805

ACHN

Bueno, mañana  lo de Trump es a las 11:30 hora usana y el discurso sera a las 12:00.

Nos agarramos los machos ya? ;)

SGYP
Ya casi a $7 en pre. Mi idea es vender 1/3 si supera los $7.5 hoy.
Dado que tienen prisa por poner el fco en el mercado,espero anuncio de secondary o BO relativamente pronto.
Los rumores de BO y el numero de shorts pueden hacer un salto en el precio estos días.

Conoceis Myovant (MYOV) ? actualmente estoy haciendo DD. Los expertos en gráficos a ver si me pueden comentar buenos puntos para posible entrada.
Myovant, desarrollando un GnRH receptor antagonist, Relugolix para endometriosis, uterine fibroids y advanced prostate cancer.

no tengo apenas historico de MYOV, de lo que tengo ... la entrada en 10bajos, claro,

Amarin Announces Debt Restructuring and Related Private Placement of Exchangeable Senior Notes

AMRN

BEDMINSTER, N.J. and DUBLIN, Ireland, Jan. 20, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN) ("Amarin") announced today that it and its wholly owned subsidiary, Corsicanto II Designated Activity Company (the "Issuer"), have entered into separate, privately negotiated purchase agreements with certain investors pursuant to which the Issuer will issue and sell $30.0 million in aggregate principal amount of 3.50% Exchangeable Senior Notes due 2047 (the "2017 Notes"), which will be guaranteed by Amarin, at an issue price of 100%. The purchase agreements were entered into in contemplation of the surrender for purchase of approximately $15.0 million aggregate principal amount of 3.50% Exchangeable Senior Notes due 2032, which were issued in January 2012 by a subsidiary of Amarin (the "2012 Notes"). As detailed in an Amarin press release issued on December 16, 2016, Amarin was required by the terms of the indenture governing the 2012 Notes to purchase all 2012 Notes surrendered to it on January 19, 2017. As of today, approximately $0.1 million aggregate principal amount of 2012 Notes remain outstanding. 

The 2017 Notes will be exchangeable into American Depositary Shares of Amarin ("ADSs") at the option of the holders at an initial exchange rate of 257.2016 ADSs per $1,000 principal amount of 2017 Notes (equivalent to an initial exchange price of approximately $3.89 per ADS), subject to adjustment in certain circumstances. The exchange price represents a premium of approximately 35% over the last reported sale price of $2.88 per share of Amarin's ADS on The NASDAQ Global Market on January 19, 2017. The transaction is expected to close on January 25, 2017, subject to customary closing conditions.

The net proceeds from the offering are expected to be $28.9 million after deducting placement agent fees and estimated offering expenses payable by Amarin.  A portion of the net proceeds from the offering will replenish approximately $15.0 million of cash on hand that Amarin used to purchase substantially all of the 2012 Notes.  Amarin anticipates that it will use such cash on hand and the remainder of the net proceeds from the offering for general corporate and working capital purposes.

Lazard is acting as financial advisor and placement agent in connection with the 2017 Notes offering.

This announcement is neither an offer to sell nor a solicitation of an offer to buy any of these securities and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful. The 2017 Notes and the ADSs issuable upon exchange of the 2017 Notes will not be registered under the Securities Act of 1933, as amended (the "Securities Act"), or the securities laws of any other jurisdiction, and may not be offered or sold in the United States absent registration under the Securities Act or an applicable exemption from registration requirements.

MYOV
A mí tampoco me sale más, framus.
Soportillo 10,8 con indicadores a la baja y le queda el mínimo en 10,25.